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Abstract Alzheimer’s disease (AD) is a neurodegenera-
tive disorder, characterized by amyloid plaque accumula-
tion, intracellular tangles and neuronal loss in selective
brain regions. The frontal cortex, important for executive
functioning, is one of the regions that are affected. Here,
we investigated the neurodegenerative effects of mutant
human amyloid precursor protein (APP) and presenilin 1
(PS1) on frontal cortex neurons in APP/PS1KI mice, a
transgenic mouse model of AD, expressing two mutations
in the human APP, as well as two human PS1 mutations
knocked-in into the mouse PS1 gene in a homozygous (ho)
manner. Although the hippocampus is significantly affec-
ted in these mice, very little is known about the effects of
these mutations on selective neuronal populations and
plaque load in the frontal cortex. In this study, cytoarchi-
tectural changes were characterized using high precision
design-based stereology to evaluate plaque load, total
neuron numbers, as well as total numbers of parvalbumin-
(PV) and calretinin- (CR) immunoreactive (ir) neurons in
the frontal cortex of 2- and 10-month-old APP/PS1KI
mice. The frontal cortex was divided into two subfields:
layers II–IV and layers V–VI, the latter of which showed
substantially more extracellular amyloid-beta aggregates.
We found a 34% neuron loss in layers V–VI in the frontal
cortex of 10-month-old APP/PS1KI mice compared to
2-month-old, while there was no change in PV- and CR-ir
neurons in these mice. In addition, the plaque load in layers
V–VI of 10-month-old APP/PS1KI mice was only 11% and
did not fully account for the extent of neuronal loss.
Interestingly, an increase was found in the total number of
PV-ir neurons in all frontal cortical layers of single trans-
genic APP mice and in layers II–IV of single transgenic
PS1ho mice between 2 and 10 months of age. In conclu-
sion, the APP/PS1KI mice provide novel insights into the
regional selective vulnerability in the frontal cortex during
AD that, together with previous findings in the hippo-
campus, are remarkably similar to the human situation.
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Introduction
Alzheimer’s disease (AD) is a severe, progressive brain
disorder that affects a significant portion of the aged pop-
ulation. The neuropathological hallmarks consist of intra-
and extracellular amyloid-beta aggregates, intracellular
neurofibrillary tangles, and dysfunction of neurons and
synapses, resulting in brain atrophy and ultimately neuron
loss that is restricted to specific brain regions (Cummings
and Cole 2002; Selkoe 2001; Dickson 2001; Probst et al.
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1991). Although AD’s neuropathology is well defined, its
etiology remains to be elucidated.
According to the amyloid cascade hypothesis, altered
amyloid processing and accumulation of aggregated amy-
loid-beta is a main causative factor in AD (Hardy and Selkoe
2002; Tanzi and Bertram 2005). Based on the identification of
specific mutations in the amyloid precursor protein (APP) and
the presenilin (PS1 and PS2) genes that are associated with
increased amyloid production, various mouse models have
been developed that mimic several aspects of AD. Although
these models allow to study spatiotemporal development of
the neuropathology of AD (Gotz and Gotz 2009), only some
actually show hippocampal cell loss (Casas et al. 2004;
Schmitz et al. 2004), a characteristic feature of the human AD
brain (Duyckaerts et al. 2009). The APP/PS1KI mouse model
investigated by Casas et al. (2004) did not only show signif-
icant neuron loss (Bayer and Wirths 2008), but also displayed
a significant decrease in the numbers of parvalbumin- (PV)
and calretinin- (CR) immunoreactive (ir) neurons in the
hippocampus (Takahashi et al. 2010).
In addition to the hippocampus, higher association areas
(Francis 2006; Miller and Cohen 2001), like the frontal
cortex (Braak et al. 1996; Price and Sisodia 1998), are
affected in AD, accounting for executive dysfunction and
many of the other higher-order cognitive deficits observed
in AD patients (Miller and Cohen 2001). The large pyra-
midal neurons, especially those in layers III and V of the
temporal and frontal cortex, are among the first to degen-
erate in AD (Morrison and Hof 2002; Brun and Englund
1981; Hof et al. 1990). Specifically, layer V pyramidal
neurons are important for long-range corticocortical, cor-
ticospinal, and corticostriatal connections (Anderson et al.
2010; Bussiere et al. 2003). Several studies reported
abnormalities in the frontal cortex in AD, particularly in
these large pyramidal neurons, which are particularly vul-
nerable (Mann et al. 1988; Mesulam and Geula 1988;
Gomez-Isla et al. 1997; Morrison and Hof 2007).
Of particular interest are neurons expressing calcium-
binding proteins (CaBP); i.e. PV-ir and CR-ir neurons (Ku-
bota and Kawaguchi 1994) that are thought to execute highly
specific inhibitory tasks during cognitive functions (Cauli
et al. 1997; Conde et al. 1994; Kawaguchi and Kubota 1997).
Despite their valuable role in cognition, the selective vul-
nerability of these PV-ir and CR-ir neurons in AD remains
unresolved (Satoh et al. 1991; Sampson et al. 1997).
The aim of this study was therefore to assess the neu-
rodegenerative effects of mutant APP and PS1 in the
frontal cortex of the APP/PS1KI mice on total neuron
numbers, numbers of PV-ir and CR-ir neurons, and plaque
load as a function of age. Based on previous studies, we
hypothesize that APP/PS1KI mice exhibit an age-related
increase in plaque load, paralleled by a decrease in overall
neuron numbers as well as in PV-ir and CR-ir neuron
numbers. We used high precision design-based stereology
to analyze layers II–IV and layers V–VI of the frontal
cortex of these mice, as well as of APP, PS1 heterozygote
(PS1he), and PS1 homozygote (PS1ho) mice as controls.
Layers II–IV and layers V–VI, respectively, of the frontal
cortex were chosen since most pathology was expected in
layers V–VI due to the selective vulnerability of large
pyramidal neurons. For each genotype, 2-month-old mice




The following groups of 2-month-old (M2) and 10-month-
old (M10) mice were obtained from Sanofi-Aventis Centre
de Recherche de Paris (Vitry sur Seine, France): APP mice
[transgenic mice expressing human mutant APP751 car-
rying the Swedish (K670N/M671L) and London (V717I)
mutations; mouse Thy-1 promoter] (n = 9; 6 male, 3
female), PS1he mice [expressing human PS1 mutations
(M233T and L235P) knocked-in into the mouse PS1 gene
in a hemizygous manner] (n = 13; 4 male, 9 female),
PS1ho mice [expressing human PS1 mutations (M233T
and L235P) knocked-in into the mouse PS1 gene in a
homozygous manner] (n = 9; 7 male, 2 female), and APP/
PS1KI mice (expressing both the aforementioned APP and
PS1ho mutations) (n = 8; 5 male, 3 female). A detailed
description of these mice was provided in the literature
(Casas et al. 2004). Due to the complicated genetic back-
ground of the mice used in this study, we decided not to
include wild-type mice in this study. Furthermore, wild-
type mice do not show significant any age-related changes
in the frontal cortex (Duyckaerts et al. 2008; Phinney et al.
2003). Since the APP mice have the same genetic back-
ground and do not show any age-related differences, these
animals can serve as an internal control. All experiments
were approved by the Aventis Animal Care and Use
Committee, in accordance with standards for the care and
use of laboratory animals formulated by the French and
European Community (Centre National de la Recherche
Scientifique, Institute of Laboratory Animal Resources).
Tissue processing
The mice were anesthetized with chloral hydrate and tran-
scardially perfused with tyrode buffer, followed by a fixative
consisting of 4% paraformaldehyde, 15% picric acid, and
0.05% glutaraldehyde in phosphate buffer (Schmitz et al.
2004). Brains were dissected from the skulls, and halved
along the mediosagittal line. The left brain halves were
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post-fixed for 2 h at 4C in the fixative, omitting the glu-
taraldehyde. Subsequently, they were cryoprotected with
30% sucrose, and thereafter quickly frozen. The frozen
brains were cut into series of 30-lm thick coronal cryostat
sections (Leica, CM3050, Wetzlar, Germany). Every tenth
section was systematically assigned to a series of sections,
yielding a total of 10 series. While cutting, each brain was
divided in three regions: frontal cortex, hippocampus, and
cerebellum. For this study, only sections from the frontal
cortex were analyzed. After cutting, the material was stored
at -80C until further processing. The right brain halves
were not included in this study.
Immunohistochemistry
To analyze volumes of brain regions, plaque load, total
neuron numbers, and PV-ir and CR-ir neuron numbers in
the frontal cortex, standard fluorescence immunohisto-
chemical detection procedures were used. One series was
used for the detection of NeuN, a neuronal marker (1:50;
monoclonal mouse anti-neuronal nuclei; Millipore, Bille-
rica, MA, USA), another was used for immunofluorescent
detection of both Parvalbumin (1:10,000; monoclonal
mouse; Swant, Bellinzona, Switzerland) and Calretinin
(1:2,000; polyclonal rabbit anti-mouse; Swant). A third
series was used to detect amyloid-beta (1:1,200; mono-
clonal mouse anti-amyloid-beta [17–24]; Sigma, St. Louis,
MO, USA); and thioflavin S was added to stain the
aggregated core of the plaques (0.015% in TBS; 10 min;
Sigma). In all protocols, Hoechst 33342 was used as DNA
counterstain (1:500 in TBS; 30 min; Sigma). Free-floating
sections were washed in tris-buffered saline (TBS) with
(TBS-T) and without (TBS) triton X-100 (Merck, Darms-
tadt, Germany). Primary antibodies were incubated over-
night at 4C in TBS-T at a specific concentration. On the
next day, the sections were washed and incubated with
secondary antibodies for 2 h at room temperature in TBS-
T. For NeuN and Parvalbumin, donkey anti-mouse IgG
Alexa Fluor 488 (1:200; Molecular Probes, Eugene, OR,
USA) was used; for Calretinin, donkey anti-rabbit IgG
Alexa Fluor 594 (1:200; Molecular Probes); and for amy-
loid-beta, donkey anti-mouse IgG Alexa Fluor 594 (1:200;
Molecular Probes). After rinsing with TBS, the sections
were mounted on gelatinized glass slides, air-dried, and
coverslipped with 80% glycerol in TBS. The immunopro-
cessed sections were microscopically checked for complete
penetration of the antibodies, resulting in immunoreactivity
evenly distributed throughout the entire section thickness.
Stereologic analyses
The sections were investigated with high precision design-
based stereology (see, e.g., Schmitz and Hof 2005). This
approach is considered the gold standard for microscopic
quantification of 3D structures and allows accurate, reli-
able, and efficient estimates of volumes of brain regions,
plaque load, and numbers of neurons within specific brain
regions.
Volumes of brain regions, and numbers of NeuN
immunoreactive neurons
Volume measurements of the frontal cortex were performed
on sections immunoprocessed for the detection of NeuN. To
this end, all sections between stereotaxic bregma coordinates
1.10 mm and -0.22 mm (Franklin and Paxinos 1997) were
selected, and the frontal cortex was delineated as described
before, drawing an angle of 45 and taking the entire area
within this triangle, from the corpus callosum up (Kantor
et al. 2006). The frontal cortex was divided into layers II–IV,
and layers V–VI, respectively. Volumes were calculated
from projection area measurements and the average actual
section thickness after histological processing, using Cav-
alieri’s principle (Gundersen and Jensen 1987). The actual
section thickness was measured with the electronic micro-
cator of a stereology workstation (described below) and a
UPlanSApo 409 objective (NA = 0.9; Olympus, Tokyo,
Japan). All details regarding the stereologic analysis were
extensively described by Schmitz and Hof (2005). Micro-
scopic inspection of the sections was performed with a Stereo
Investigator Confocal Spinning Disk (SI-SD) system (MBF
Bioscience; Williston, VT, USA), consisting of a modified
Olympus BX51 fluorescence microscope (Olympus) with
UPlanSApo objectives 109 (NA = 0.4; Olympus), 209
(NA = 0.75; Olympus) and 409 (NA = 0.9; Olympus),
customized spinning disk unit (DSU; Olympus), computer-
controlled excitation and emission filter wheels (Olympus),
three-axis high-accuracy computer-controlled stepping
motor specimen stage (4 9 4 Grid Encoded Stage; Ludl
Electronic Products, Hawthorne, NY, USA), linear z-axis
position encoder (Ludl), ultra-high sensitivity monochrome
electron multiplier CCD camera (1,000 9 1,000 pixels,
C9100-02; Hamamatsu Photonics, Hamamatsu City, Japan),
and controlling software (StereoInvestigator; MBF Biosci-
ence). The Optical Fractionator Probe was used to quantify
numbers of NeuN-ir cells. The surface area of the unbiased
virtual counting spaces (UVCS) used to count the neurons
was 900 lm2, the height of the UVCS was 14 lm (upper and
lower guard zones were 1.5 lm each), and the distance
between the UVCS in orthogonal directions X and Y was 250
and 125 lm, respectively. Cells were counted if they fell
inside the unbiased virtual counting frame and the top of the
nucleus came into focus within the optical disector height.
The counting variability was measured with the Schmitz–
Hof coefficient of error (CE) (Schmitz 1998). The CE for of
both layers II–IV and layers V–VI was 0.057.
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Numbers of PV-ir and CR-ir neurons
The numbers of PV-ir and CR-ir neurons were assessed
with a computerized stereology workstation, consisting of a
modified fluorescent light microscope (Olympus BX50),
motorized specimen stage for automatic sampling (Ludl),
focus drive linear encoder (Ludl Electronics), CCD colour
video camera (HVC20AMP; Hitachi, Tokyo, Japan), and
stereology software (StereoInvestigator; MBF Bioscience).
All PV-ir and CR-ir neurons coming into focus within the
section thickness were counted (Takahashi et al. 2010).
Then, densities of PV-ir and CR-ir neurons were calculated
by dividing the number of counted neurons per region (i.e.,
layers II–IV and layers V–VI, respectively) by the product
of the cut section thickness (30 lm) with the sum of all
cross-sectional areas of this region. This was valid as all
PV-ir and CR-ir neurons coming into focus within the
section thickness were counted. Numbers of PV-ir and CR-
ir neurons were obtained by multiplying the volumes of
layers II–IV and layers V–VI with the densities of PV-ir
and CR-ir neurons within the corresponding regions. For
the delineation of the entire frontal cortex or layers II–IV
and layers V–VI, respectively, a 109 objective was used
(UplanApo, NA = 0.40), and for counting PV-ir and CR-ir
neurons a 409 oil objective (UplanApo, NA = 1.00). The
base of the UVCS used to count neurons was the same as
the grid size, namely 125 lm (X) by 100 lm (Y) and the
measured actual average section thickness after histologi-
cal processing was 20.55 lm (Schmitz 1998). The counting
variability was measured with the Schmitz–Hof coefficient
of error (CE) (Schmitz 1998). The CE for PV-ir neurons
was 0.041 and for the CR-ir neurons, the CE was 0.064.
Plaque load
The plaque load was analyzed with the same stereology
workstation that was used to determine the numbers of the PV-
ir and CR-ir neurons, using a 409 oil objective (UplanApo,
NA = 1.00). Both markers for amyloid plaques (amyloid-
beta and thioflavin S) were analyzed as relative volumes with
the Cavalieri probe of the StereoInvestigator software (MBF
Bioscience) and a grid size of 20 lm 9 20 lm. The Cavalieri
probe is implemented by overlaying a rectangular lattice of
points on the frontal cortex and then counting the number of
points in the lattice that lie within a plaque.
Statistical analysis
For each group of mice, mean and standard error of the
mean were calculated for the estimated volumes of brain
regions, plaque load, overall neuron numbers, and PV-ir
and CR-ir neuron numbers. Comparisons between 2- and
10-month-old animals were performed with two-way
analysis of variance (ANOVA; univariate; with age and
genotype as fixed factors) followed by post-hoc Bonfer-
roni’s multiple comparison test for pair-wise comparisons.
Statistical significance was established at p \ 0.05. Cal-
culations were performed using GraphPad Prism (Version
4.00 for Windows; GraphPad Software, San Diego, CA,
USA).
Photography
All photomicrographs were captured with the SI–SD sys-
tem described above (MBF Bioscience). Only minor
adjustments were made in brightness and contrast, without
changing the original content of the pictures.
Results
Volume of the frontal cortex
The mean volume of the frontal cortex (or of respectively
layers II–IV and layers V–VI within the frontal cortex) did
not differ significantly among the groups of mice (Fig. 1;
Fig. 1 Mean and standard error of the mean (SEM) of volumes of
layers II–IV (a), layers V–VI (b), and the entire frontal cortex (c) of
2-month-old (open bars) and 10-month-old (closed bars) APP mice,
PS1he mice, PS1ho mice, and APP/PS1KI mice. Statistical analysis
did not reveal significant differences among the groups of mice
(p \ 0.05)
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all significant p values of the ANOVAs are summarized in
Table 1).
The mean volume ± SEM (in mm3) for the total frontal
cortex was 1.330 ± 0.119 for APP M2; 1.500 ± 0.042 for
APP M10; 1.629 ± 0.218 for PS1he M2; 1.471 ± 0.046 for
PS1he M10; 1.331 ± 0.068 for PS1ho M2; 1.416 ± 0.139
for PS1ho M10; 1.422 ± 0.117 for APP/PS1KI M2 and
1.275 ± 0.066 for APP/PS1KI M10. The mean volume ±
SEM (in mm3) for layers II–IV was 0.518 ± 0.041 for APP
M2; 0.582 ± 0.021 for APP M10; 0.666 ± 0.090 for PS1he
M2; 0.548 ± 0.023 for PS1he M10; 0.516 ± 0.028 for
PS1ho M2; 0.542 ± 0.044 for PS1ho M10; 0.544 ± 0.038
for APP/PS1KI M2 and 0.546 ± 0.031 for APP/PS1KI
M10. The mean volume ± SEM (in mm3) for layers V–VI
was 0.652 ± 0.068 for APP M2; 0.754 ± 0.025 for APP
M10; 0.773 ± 0.115 for PS1he M2; 0.767 ± 0.024 for
PS1he M10; 0.662 ± 0.032 for PS1ho M2; 0.723 ± 0.080
for PS1ho M10; 0.704 ± 0.062 for APP/PS1KI M2 and
0.613 ± 0.044 for APP/PS1KI M10.
Numbers of NeuN-ir, PV-ir, and CR-ir neurons
In layers II–IV of the frontal cortex, the mean number of
NeuN-ir neurons did not differ significantly among the
groups of mice (Fig. 2). In contrast, a statistically signifi-
cant decrease of 34% was found in the mean number of
NeuN-ir neurons in layers V–VI of the frontal cortex in
APP/PS1KI mice at M10 compared to M2 (Table 1;
Figs. 2b, 3). The mean number of NeuN-ir neurons ±
SEM for layers II–IV was 74,100.850 ± 9,534.305 for
APP M2; 101,155.700 ± 4,778.673 for APP M10;
118,913.400 ± 21,318.720 for PS1he M2; 98,809.700 ±
8,171.961 for PS1he M10; 81,321.560 ± 8,705.061 for
PS1ho M2; 111,689.200 ± 13,577.850 for PS1ho M10;
96,401.660 ± 6,566.594 for APP/PS1KI M2 and
88,737.490 ± 2,714.963 for APP/PS1KI M10. The mean
number of NeuN-ir neurons ± SEM for layers V–VI was
94,070.380 ± 12,013.250 for APP M2; 90,665.040 ±
3,728.086 for APP M10; 105,525.300 ± 17,185.940 for
PS1he M2; 101,437.200 ± 3,994.310 for PS1he M10;
90,533.980 ± 2,619.225 for PS1ho M2; 99,831.590 ±
9,228.039 for PS1ho M10; 95,491.390 ± 5,957.515 for
APP/PS1KI M2 and 63,374.960 ± 5,099.795 for APP/
PS1KI M10.
The mean numbers of CR-ir neurons showed no signifi-
cant differences among the groups of mice (Figs. 2c, d, 4). In
contrast, the mean numbers of PV-ir neurons did differ sig-
nificantly (Table 1; Figs. 2e, f, 4). Surprisingly, the APP
mice showed a significant (p \ 0.05) age-related increase in
the mean total numbers of PV-ir neurons in both layers II–IV
and layers V–VI between M2 and M10. A similar age-related
increase was found in the mean number of PV-ir neurons in
layers II–IV of the PS1ho mice, but not the PS1he mice or the
APP/PS1KI mice. The mean number of CR-ir neurons ±
SEM for layers II–IV was 3,220.667 ± 334.491 for APP
M2; 3,669.833 ± 149.847 for APP M10; 3,043.667 ±
299.130 for PS1he M2; 3,247.143 ± 270.756 for PS1he
M10; 2,961.000 ± 216.431 for PS1ho M2; 2,939.000 ±
319.162 for PS1ho M10; 2,530.000 ± 693.574 for APP/
PS1KI M2 and 2,960.667 ± 187.024 for APP/PS1KI M10.
The mean number of CR-ir neurons ± SEM for layers V–VI
was 1,195.667 ± 203.851 for APP M2; 1,244.833 ±
104.241 for APP M10; 1,027.667 ± 145.502 for PS1he M2;
1,050.000 ± 86.112 for PS1he M10; 903.250 ± 100.945
for PS1ho M2; 988.250 ± 33.807 for PS1ho M10;
872.000 ± 150.742 for APP/PS1KI M2 and 913.000 ±
62.386 for APP/PS1KI M10. The mean number of PV-ir
neurons ± SEM for layers II–IV was 4,005.333 ± 218.155
for APP M2; 5,865.667 ± 249.856 for APP M10;
5,538.000 ± 386.355 for PS1he M2; 5,330.857 ± 452.588
for PS1he M10; 3,983.250 ± 616.890 for PS1ho M2;
5,808.250 ± 309.408 for PS1ho M10; 5,012.333 ± 657.345
for APP/PS1KI M2 and 5,126.333 ± 76.062 for APP/PS1KI
M10. The mean number of PV-ir neurons ± SEM for layers
V–VI was 4,161.333 ± 269.094 for APP M2; 5,470.000 ±
182.240 for APP M10; 5,200.667 ± 154.942 for PS1he M2;
4,484.000 ± 263.349 for PS1he M10; 4,194.000 ± 480.449
for PS1ho M2; 4,836.500 ± 345.734 for PS1ho M10;
4,778.667 ± 201.878 for APP/PS1KI M2 and 3,789.333 ±
321.910 for APP/PS1KI M10.
Plaque load
Both APP mice and APP/PS1KI mice showed an age-
related increase in the mean plaque load between M2 and
M10 in the frontal cortex (Table 1; Figs. 5, 6). In the
frontal cortex of the APP/PS1KI mice, the mean plaque
load (immunohistochemical detection of amyloid-beta)
increased in layers II–IV from 0.2% at M2 to 7.3% at
M10, and in layers V–VI from 1% at M2 to 11.3% at
M10. PS1he and PS1ho mice did not exhibit amyloid
plaques.
Table 1 Overview of significant ANOVA p values (\0.05), for both
fixed factors (age and genotype) and their interaction




NeuN-ir neurons in layers V–VI 0.1746 0.0304 0.1746
PV-ir neurons in layers II–IV 0.0111 0.6076 0.0528
PV-ir neurons in layers V–VI 0.7887 0.3007 0.0037
Amyloid-beta in layers II–IV <0.0001 <0.0001 <0.0001
Amyloid-beta in layers V–VI <0.0001 <0.0001 <0.0001
Thioflavin S in layers II–IV <0.0001 <0.0001 <0.0001
Thioflavin S in layers V–VI <0.0001 <0.0001 <0.0001
Bold values are statistically significant (i.e. p \ 0.05)
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Fig. 2 Mean and standard error
of the mean (SEM) of numbers
of NeuN-ir neurons (a, b), CR-ir
neurons (c, d), and PV-ir
neurons (e, f) within layers II–
IV (a, c, e) and layers V–VI (b,
d, f) of 2-month-old (open bars)
and 10-month-old (closed bars)
APP mice, PS1he mice, PS1ho
mice, and APP/PS1KI mice.
Statistical analysis revealed
significant (pANOVA \ 0.05)
differences among the groups of
mice in b (numbers of NeuN-ir
neurons within layers V–VI),
e (numbers of PV-ir neurons
within layers II–IV), and
f (numbers of PV-ir neurons
within layers V–VI),
respectively. Results of post-hoc
Bonferroni’s multiple
comparison test for pair-wise
comparisons are indicated by
asterisks (*p \ 0.05)
Fig. 3 Representative
photomicrographs of coronal
sections showing the frontal
cortex of 2- (a) and 10-month-
old (b) APP/PS1KI mice,
immunoprocessed for the
detection of NeuN. Note the
age-related increase in the
plaque load (holes, indicated by
arrows). The scale bar
represents 100 lm
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The mean percentage of plaque load ± SEM for layers
II–IV was 0.000 ± 0.000 for APP M2 (amyloid-beta and
thioflavin S); 2.027 ± 0.008 for APP M10 (amyloid-beta);
0.954 ± 0.000 for APP M10 (thioflavin S); 0.178 ± 0.110
for APP/PS1KI M2 (amyloid-beta); 0.025 ± 0.025 for
APP/PS1KI M2 (thioflavin S); 7.260 ± 0.643 for APP/
PS1KI M10 (amyloid-beta) and 3.363 ± 0.210 for APP/
PS1KI M10 (thioflavin S). The mean percentage of plaque
load ± SEM for layers V–VI was 0.000 ± 0.000 for APP
M2 (amyloid-beta and thioflavin S); 3.826 ± 0.066 for
APP M10 (amyloid-beta); 3.155 ± 0.000 for APP M10
(thioflavin S); 0.956 ± 0.101 for APP/PS1KI M2 (amy-
loid-beta); 0.470 ± 0.108 for APP/PS1KI M2 (thioflavin
S); 11.260 ± 2.177 for APP/PS1KI M10 (amyloid-beta);
and 8.112 ± 0.044 for APP/PS1KI M10 (thioflavin S).
Discussion
The present study resulted in two main findings that were
not reported in the literature before: (i) unlike APP mice,
PS1he mice and PS1ho mice, APP/PS1KI mice showed an
age-related, averaged 34% loss of neurons in layers V–VI
of the frontal cortex between M2 and M10, which exceeded
the plaque load in these cortical layers. (ii) APP mice and
PS1ho mice, but not PS1he mice and APP/PS1KI mice,
showed an age-related increase in the mean total numbers
of PV-ir neurons in cortical layers II–IV between M2 and
M10 (APP mice also in layers V–VI).
With respect to the age-related neuron loss in layers V–
VI, but not in layers II–IV, of the frontal cortex of the APP/
PS1KI mice, the data reported by Christensen et al. (2008)
is in line with our study. These authors also investigated
neuron loss in the frontal cortex of APP/PS1KI mice with
design-based stereology, and found—compared to PS1ho
mice—an average 30% neuron loss in the frontal cortex
between M2 and M10, and an age-related increase in
average plaque load from 5% at M2 to 13% at M10.
However, unlike in the present study, Christensen et al.
(2008) did not perform layer-specific analyses of neuron
numbers, did not investigate the frontal cortex of APP mice
and PS1he mice, and did not study numbers of CR-ir and
PV-ir neurons. Based on light microscopic analysis of
immunohistochemical detection of amyloid-beta, Chris-
tensen et al. (2008) concluded that age-related neuron loss
in the frontal cortex of APP/PS1KI mice was due to tran-
sient intraneuronal amyloid-beta, rather than extracellular
plaque pathology.
The finding that the extent of age-related neuron loss
could not be accounted for by the coverage of the plaque
load was also observed in the hippocampal CA1/2 region
of APP/PS1KI mice at M10 compared to M2 (Casas et al.
2004) as well as in the hippocampal CA1/2 region of
double transgenic APP751/PS1M146L mice at M17 com-
pared to M2 (Schmitz et al. 2004). Thus, it appears that
neuron loss in transgenic mouse models of AD is not just
the result of the occurrence of extracellular amyloid-beta
plaques (also discussed in Bayer and Wirths 2008; Wirths
et al. 2010). The same appears to happen in human AD
(Gomez-Isla et al. 1997) where the clinical severity of AD
cannot be predicted from the amount of amyloid-beta
plaques alone, and substantial numbers of amyloid-beta
plaques can be present in otherwise symptom-free elderly
(Giannakopoulos et al. 2003). It has been suggested that
intraneuronal amyloid-beta aggregates could be a major
contributing early factor for neuron loss in human AD, as
well as in transgenic mouse models of AD. In this regard,
abundant intraneuronal amyloid-beta 40–42, together with
neuronal stress markers, is known to be present before the
occurrence of extracellular amyloid-beta plaques in hip-
pocampal neurons of double transgenic APP751/PS1M146L
mice (Wirths et al. 2001). Obviously, this neuron loss may
be accompanied, or even preceded, by other signs of neu-
ropathology, such as synapse loss (Moechars et al. 1999;
Pratico et al. 2001).
Fig. 4 Representative photomicrograph of CV-ir neurons (red) and
PV-ir neurons (green) in the frontal cortex of a 2-month-old PS1ho
mouse. The picture was created by montaging a total of 573 high-
resolution fields-of-view into a single two-dimensional virtual slide.
The scale bar represents 200 lm
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The age-related increase in the total number of PV-ir
neurons in the frontal cortex of 10-month-old APP mice
and PS1ho mice was unexpected and this study is therefore,
to our knowledge, the first to report such an age-related
increase in a mouse model of AD. In contrast, the hippo-
campus of PS1he mice, PS1ho mice and APP/PS1KI mice
showed a complex pattern of age-related loss of CR-ir and
PV-ir neurons in the different hippocampal subregions, but
no age-related increase in the numbers of these neurons
(Takahashi et al. 2010). This indicates that the increase in
the number of PV-ir neurons in APP mice and PS1ho mice
is region-specific.
Conflicting reports exist about the fate of CR-ir and PV-
ir neurons in AD. While some studies stated that PV-ir
neurons are resistant to AD pathology (Ferrer et al. 1991;
Hof et al. 1991; Sampson et al. 1997), other studies
reported significant loss of these neurons in both hippo-
campus and cortex (Arai et al. 1987; Brady and Mufson
1997; Mikkonen et al. 1999; Satoh et al. 1991; Solodkin
et al. 1996).
A possible explanation for the age-related increase in
PV-ir neuron number in the frontal cortex of APP mice and
PS1ho mice could be proliferation. However, although
postnatal neurogenesis could in theory be implicated, it
appears—if at all existent—very rare, particularly in the
adult cortex (Thompson et al. 2008; Rakic 2002; Gould
2007; Marlatt and Lucassen 2010). An alternative option
could be the presence of delayed differentiation. Next to its
well-known toxic properties (Trotti et al. 1998; Mattson
et al. 1992), amyloid-beta can also serve as a neurotrophic
factor for differentiating neurons (Yankner et al. 1990;
Kwak et al. 2006). Based on these opposite aspects of
amyloid-beta, one could postulate that the mutations in
APP and PS1 induced an overproduction of amyloid-beta,
which—due to its neurotrophic function—could have ini-
tially promoted neuronal growth, development and sur-
vival, resulting in (delayed) differentiation of PV-ir
neurons in the frontal cortex of APP mice and PS1ho mice.
However, when all mutations are combined in APP/PS1KI
mice, this may have resulted in an excessive amount of
Fig. 5 Mean and standard error of the mean (SEM) of the plaque
load within layers II–IV (a, c) and layers V–VI (b, d) of the frontal
cortex of 2-month-old (open bars) and 10-month-old (closed bars)
APP mice and APP/PS1KI mice, analyzed by immunohistochemical
detection of amyloid-beta (a, b) or staining of the plaque cores with
thioflavin S (c, d), respectively. Statistical analysis revealed signi-
ficant (pANOVA \ 0.05) differences among the groups of mice in
a–d. Results of post-hoc Bonferroni’s multiple comparison test for
pair-wise comparisons are indicated by asterisks (**p \ 0.01;
***p \ 0.001). PS1he and PS1ho mice did not exhibit amyloid
plaques. The SEM of APP mice (all graphs) and 10-month-old APP/
PS1 mice are not shown because the interindividual variation was too
small
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amyloid-beta through which its toxic effects overruled
effects on neuronal differentiation.
Alternatively, a delayed differentiation (or proliferation)
could occur as a protective mechanism triggered by initial
toxic effects of amyloid-beta. Such a protective or com-
pensatory mechanism could be involved in amyloid-beta
action particularly in the APP mice and PS1ho mice, and at
least partly explain the results of the present study.
Although not investigated in great detail, previous studies
have suggested neurotrophic and proliferative effects of
selective amyloid-beta fragments in in vitro models, as
well as in the response of neurogenesis in some AD mouse
models (Marlatt and Lucassen 2010; Kuhn et al. 2007;
Thompson et al. 2008). Together, these results indicate that
in response to a pathogenic stimulus, neuronal de-differ-
entiation and reengagement in cell cycle may occur, but
only under restricted conditions and in specific subregions
of the brain. An additional explanation in this regard is that
the age-related increase in the mean numbers of PV-ir
neurons in the frontal cortex of APP mice and PS1ho mice
could occur in an attempt to protect pyramidal neurons
against excitotoxicity. Finally, a less obvious mechanism
could involve alterations in migration processes of neurons,
since it is known that both APP and PS1 are involved in
neurodevelopment. Loss of PS1 function was shown to
inhibit normal migratory trajectories of neurons during
neurodevelopment (Louvi et al. 2004), and deficiency of
APP further reduces not only viability of postnatal mice but
also produces cortical developmental abnormalities that
resemble lissencephaly, a cortical condition in which no
normal gyri are formed in the brain of humans (Herms
et al. 2004).
Considering these three possible mechanisms, the most
likely explanation for the age-related increase in the mean
numbers of PV-ir neurons in the frontal cortex of APP mice
and PS1ho mice would be altered or delayed neuronal
differentiation. Thus, the present changes may be the result
of a complex interplay of pathological as well as physio-
logical roles of the APP and PS1 proteins and needs to be
addressed in detail in future studies.
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Fig. 6 Representative
photomicrographs of plaque
load in layers V–VI of the
frontal cortex of 2- and
10-month-old APP (a, b) and
APP/PS1KI mice (c, d).
Amyloid-beta is shown in red,
thioflavin S in green and
Hoechst in blue. Since PS1he
and PS1ho mice do not have
plaques, these mice were not
included in the figure. Each
image is the maximum intensity
projection of a complete
confocal image stack of 15 lm
thick on average, with a
distance between the single
images of 0.5 lm. The scale bar
represents 50 lm
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